Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

被引：2

作者：

Tournilhac, Olivier ^{[1
]}

Lecolant, Solene ^{[2
]}

Hacini, Maya ^{[3
]}

Bouabdallah, Krimo ^{[4
]}

Bailly, Sebastien ^{[5
]}

Laribi, Kamel ^{[6
]}

Belmondo, Thibaut ^{[7
,8
,9
]}

Maerevoet, Marie ^{[10
]}

Ysebaert, Loic ^{[11
]}

Guidez, Stephanie ^{[12
]}

Le Gouill, Steven ^{[13
]}

Bonnet, Christophe ^{[14
]}

Andre, Marc ^{[15
]}

Dupuis, Jehan ^{[16
]}

Thieblemont, Catherine ^{[17
]}

Bachy, Emmanuel ^{[18
]}

Daguindau, Nicolas ^{[19
]}

Morschhauser, Franck ^{[20
,21
,22
]}

Tricot, Sabine ^{[23
]}

Feugier, Pierre ^{[24
]}

Banos, Anne ^{[25
]}

Lamy, Thierry ^{[26
]}

Chauchet, Adrien ^{[27
]}

Gyan, Emmanuel ^{[28
]}

Cartron, Guillaume ^{[29
]}

Farhat, Hassan ^{[30
]}

Camus, Vincent ^{[31
]}

Drenou, Bernard ^{[32
]}

Zerazhi, Hacene ^{[33
]}

Sibon, David ^{[34
]}

Nicolas-Virelizier, Emmanuelle ^{[35
]}

Delette, Caroline ^{[36
]}

Snauwaert, Sylvia ^{[37
]}

Straetmans, Nicole ^{[38
]}

Delarue, Richard ^{[39
]}

Parrens, Marie ^{[40
]}

Griolet, Samuel ^{[41
]}

Gaulard, Philippe ^{[42
]}

Delfau-Larue, Marie-Helene ^{[43
]}

De Leval, Laurence ^{[44
,45
]}

Damaj, Gandhi Laurent ^{[46
]}

机构：

[1] Univ Clermont Auvergne, CHU, Serv Hematol Clin & Therapie Cellulaire, EA7453 Chelter CIC 1405, Clermont Ferrand, France

[2] Grp Hosp Henri Mondor, AP HP, Dept Biol Hematol & Immunol, Lab Immunol, Creteil, France

[3] Ctr Hosp Metropole Savoie, Hematol, Chambery, France

[4] CHU Bordeaux, Hematol & Cellular Therapy Dept, Pessac, France

[5] CHU Clermont Ferrand, Hematol & Therapie Cellulaire, Clermont Ferrand, France

[6] CH Le Mans, Hematol Clin, Le Mans, France

[7] Grp Hosp Henri Mondor, Dept Biol Hematol & Immunol, Creteil, France

[8] Grp Hosp Henri Mondor, Lab Immunol, Creteil, France

[9] Grp Hosp Henri Mondor, AP HP, Creteil, France

[10] ULB, Inst Jules Bordet, Hematol, Brussels, Belgium

[11] IUCT Oncopole, Toulouse, France

[12] CHU Poitiers, Serv Hematol & Therapie Cellulaire, CIC INSERM 1402, Poitiers, France

[13] Inst Curie Comprehens Canc Ctr, Paris, France

[14] CHU Univ Liege, Clin Hematol, Liege, Belgium

[15] Catholic Univ Louvain, Dept Hematol, CHU UCL Namur, Yvoir, Belgium

[16] Henri Mondor Univ Hosp, Lymphoid Malignancies Dept, Creteil, France

[17] Univ Paris Cite, St Louis Univ Hosp, AP HP, Hematooncol Dept, Paris, France

[18] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[19] CH Annecy Genevois, Hematol Dept, Annecy, France

[20] CHU Lille, Serv Malad Sang, F-59000 Lille, France

[21] Univ Lille 2, Ctr Hosp Reg Univ CHRU Lille, Dept Clin Hematol, Lille, France

[22] Univ Lille 2, Unite Grp Rech Formes Injetables & Technol Associ, Lille, France

[23] CH Valenciennes, Serv Hematol Clin, Valenciennes, France

[24] Henri Poincare Univ, Dept Hematol, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France

[25] Ctr Hosp Bayonne, Serv Hematol, Bayonne, France

[26] CHU Rennes, Serv Hematol Clin, Rennes, France

[27] CHU Besancon, Hematol, Besancon, France

[28] CHU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[29] CHU Montpellier, Dept Hematol Clin, Montpellier, France

[30] Hop Andre Mignot, Dept Hematol, Ctr Hosp Versailles, Le Chesnay, France

[31] Ctr Henri Becquerel, Dept Clin Hematol, Rouen, France

[32] Grp Hosp Reg Mulhouse Sud Alsace GHRMSA, Serv Hematol, Mulhouse, France

[33] CH Avignon, Hematol, Avignon, France

[34] Paris Est Creteil Univ, Fac Med & Hlth, Campus Henri Mondor, Creteil, France

[35] Ctr Leon Berard, Hematol, Lyon, France

[36] CHU Amiens, Serv Hematol Clin & Therapie Cellulaire, Amiens, France

[37] Acad Hosp St Jan, Brugge, Belgium

[38] Clin Univ St Luc, Dept Hematol, Woluwe St Lambert, Belgium

[39] Necker Univ Hosp, AP HP, Hematol Dept, Hemophilia Ctr, Paris, France

[40] Univ Bordeaux, Dept Pathol, Bordeaux, France

[41] Ctr Hosp Lyon Sud, Lymphoma Acad Res Org LYSARC, Lyon, France

[42] Henri Mondor Hosp, AP HP, Paris Est Creteil UPEC Univ Fac, Dept Pathol,INSERM UMR S 955, Creteil, France

[43] CHU Henri Mondor, AP HP, Biol Hematol & Immunol Dept, Creteil, France

[44] Lausanne Univ Hosp, Dept Lab Med & Pathol, Inst Pathol, Lausanne, Switzerland

[45] Lausanne Univ, Lausanne, Switzerland

[46] Univ Hosp Sch Med, Dept Hematol, Hematol Inst, Caen, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165217

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2302 / 2305

页数：4

共 50 条

[1] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Tournilhac, Olivier
Hacini, Maya
Bouabdallah, Kamal
Laribi, Kamel
Maerevoet, Marie
Ysebaert, Loic
Guidez, Stephanie
Le Gouill, Steven
Andre, Marc
Dupuis, Jehan
Thieblemont, Catherine
Bachy, Emmanuel
Daguindau, Nicolas
Morschhauser, Franck
Tricot, Sabine
Feugier, Pierre
Banos, Anne
De la Chapelle, Thierry Lamy
Chauchet, Adrien
Gyan, Emmanuel
Cartron, Guillaume
Farhat, Hassan
Camus, Vincent
Drenou, Bernard
Zerazhi, Hacene
Sibon, David
Nicolas-Virelizier, Emmanuelle
Delette, Caroline
Snauwaert, Sylvia
Straetmans, Nicole
Delarue, Richard
Parrens, Marie
Bossard, Celine
De Leval, Laurence
Gaulard, Philippe
Damaj, Gandhi Laurent
BLOOD, 2020, 136
[2] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
Kaleka, Guneet
Moskoff, Benjamin
Zafar, Aneeqa
Esteghamat, Naseem S.
Abedi, Mehrdad
Socola, Francisco Andres
Hoeg, Rasmus T.
Tuscano, Joseph M.
BLOOD, 2024, 144 : 6318 - 6319
[3] Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Zinzani, Pier Luigi
Salles, Gilles
Moskowitz, Alison J.
Santoro, Armando
Mehta, Amitkumar
Barr, Paul M.
Mehta-Shah, Neha
Collins, Graham P.
Ansell, Stephen M.
Brody, Joshua D.
Domingo-Domenech, Eva
Johnson, Nathalie A.
Cunningham, David
Ferrari, Silvia
Lisano, Julie
Krajewski, Jennifer
Wen, Rachael
Akyol, Alev
Crowe, Russell
Savage, Kerry J.
BLOOD ADVANCES, 2024, 8 (10) : 2400 - 2404
[4] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
Ashkar, Ryan
Feldman, Darren R.
Adra, Nabil
Zaid, Mohammad Abu
Funt, Samuel A.
Althouse, Sandra K.
Perkins, Susan M.
Snow, Christin I.
Lazzara, Kayla M.
Sego, Lina M.
Quinn, David I.
Hanna, Nasser H.
Einhorn, Lawrence H.
Albany, Costantine
INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1656 - 1663
[5] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
Ryan Ashkar
Darren R. Feldman
Nabil Adra
Mohammad Abu Zaid
Samuel A. Funt
Sandra K. Althouse
Susan M. Perkins
Christin I. Snow
Kayla M. Lazzara
Lina M. Sego
David I. Quinn
Nasser H. Hanna
Lawrence H. Einhorn
Costantine Albany
Investigational New Drugs, 2021, 39 : 1656 - 1663
[6] Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.
Gressin, Remy
Damaj, Gandhi Laurent
Bouabdallah, Kamal
Cartron, Guillaume
Choufi, B.
Gyan, Emmanuel
Jaccard, Arnaud
Park, Sophie
De Colella, Jean-Marc Schiano
Voillat, Laurent
Joly, Bertrand
Le Gouill, Steven
Saad, Alain
Sanhes, Laurence
Moles-Moreau, Marie-Pierre
Bubenheim, Michael
Bene, Marie C.
Martin, Antoine
Marolleau, Jean Pierre
Lamy, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
Advani, Ranjana
Oki, Yasuhiro
Shustov, Andrei R.
Grove, Laurie E.
Bartlett, Nancy
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[8] Brentuximab vedotin in the treatment of relapsed/refractory CD30+peripheral T-cell lymphoma: A FIL phase 2 study
Stefoni, Vittorio
Pellegrini, Cinzia
Argnani, Lisa
Corradini, Paolo
Dodero, Anna
Orsucci, Lorella
Volpetti, Stefano
Zinzani, Pier Luigi
HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 307 - 309
[9] Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
Querfeld, Christiane
Kuzel, Timothy M.
Kim, Youn H.
Porcu, Pierluigi
Duvic, Madeleine
Musiek, Amy
Rook, Alain H.
Mark, Lawrence A.
Pinter-Brown, Lauren
Hamid, Oday
Lin, Boris
Bian, Ying
Boye, Mark
Day, Jeannette M.
Rosen, Steven T.
LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1474 - 1480
[10] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Chen, Robert W.
Palmer, Joycelynne M.
Herrera, Alex Francisco
Armenian, Saro H.
Mei, Matthew
Popplewell, Leslie
Fueger, Abbey
Qasim, Imran
Stiller, Tracy
Rosen, Steven T.
Forman, Stephen J.
Kwak, Larry W.
BLOOD, 2017, 130

← 1 2 3 4 5 →